As advised via PHARMAC Tender Results of 31 July 2019 there is to be a change in the listing and future sole supply of Paraffin White Soft.

New listing from 1 November 20198

Paraffin White Soft healthE 500gm , pot                                                                           Pharmacode TBA                                    Schedule price $4.99

Paraffin White Soft healthE 2500 gm, bucket                                                                  Pharmacode TBA                                    Schedule price $19.99

Incumbent brand

Paraffin White Soft PSM/API 500 gm, pot                                                                        Pharmacode 221783                     Schedule price $3.58 (partial subsidy – manufacturer cost $8.69)

Paraffin White Soft IPW/MC 500 gm, pot                                                                         Pharmacode 768804                      Schedule price $3.58 (partial subsidy – manufacturer cost $7.78)

Paraffin White Soft IPW/MC 2500 gm, bucket                                                                Pharmacode 779679                      Schedule price $20.20

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 April 2020.

Brand switch fee not notified in July 2019 Tender.

As of the date of this notification ProPharma / PWR cannot accept Paraffin White Soft PSM/API or IPW/MC for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 April 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 April 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author